Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2023 Oct 25:2023.10.25.23297530.
doi: 10.1101/2023.10.25.23297530.

Viral and host factors associated with SARS-CoV-2 disease severity in Georgia, USA

Affiliations

Viral and host factors associated with SARS-CoV-2 disease severity in Georgia, USA

Ludy R Carmola et al. medRxiv. .

Update in

  • Viral and host factors associated with SARS-CoV-2 disease severity in Georgia, USA.
    Carmola LR, Roebling AD, Khosravi D, Langsjoen RM, Bombin A, Bixler B, Reid A, Chen C, Wang E, Lu Y, Zheng Z, Zhang R, Nguyen PV, Arthur RA, Fitts E, Gulick DA, Higginbotham D, Taz A, Ahmed A, Crumpler JH, Kraft C, Lam WA, Babiker A, Waggoner JJ, Openo KP, Johnson LM, Westbrook A, Piantadosi A. Carmola LR, et al. PLoS One. 2025 Apr 1;20(4):e0317972. doi: 10.1371/journal.pone.0317972. eCollection 2025. PLoS One. 2025. PMID: 40168303 Free PMC article.

Abstract

While SARS-CoV-2 vaccines have shown strong efficacy, their suboptimal uptake combined with the continued emergence of new viral variants raises concerns about the ongoing and future public health impact of COVID-19. We investigated viral and host factors, including vaccination status, that were associated with SARS-CoV-2 disease severity in a setting with low vaccination rates. We analyzed clinical and demographic data from 1,957 individuals in the state of Georgia, USA, coupled with viral genome sequencing from 1,185 samples. We found no difference in disease severity between individuals infected with Delta and Omicron variants among the participants in this study, after controlling for other factors, and we found no specific mutations associated with disease severity. Compared to those who were unvaccinated, vaccinated individuals experienced less severe SARS-CoV-2 disease, and the effect was similar for both variants. Vaccination within 270 days before infection was associated with decreased odds of moderate and severe outcomes, with the strongest association observed at 91-270 days post-vaccination. Older age and underlying health conditions, especially immunosuppression and renal disease, were associated with increased disease severity. Overall, this study provides insights into the impact of vaccination status, variants/mutations, and clinical factors on disease severity in SARS-CoV-2 infection when vaccination rates are low. Understanding these associations will help refine and reinforce messaging around the crucial importance of vaccination in mitigating the severity of SARS-CoV-2 disease.

Keywords: SARS-CoV-2; disease severity; post-vaccine infection.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors have declared that no competing interests exist.

Figures

Figure 1.
Figure 1.. COVID-19 cases from May 2021-May 2022 in Georgia, US.
A. 1,957 Emory Healthcare COVID-19 case mapped by counties in and around Atlanta, GA. B. Percent of population fully vaccinated against SARS-CoV-2 by May 2022 in each state in the United States. Red line represents national average (66.7%). Red bar represents Georgia. C. Proportion of variants circulating in Georgia from April 2021- June 2022. Sequences obtained from GISAID.
Figure 2.
Figure 2.. Frequencies of single nucleotide polymorphisms (SNPs) among SARS-COV-2 genome sequences from vaccinated and unvaccinated individuals.
Each point represents a single SNP plotted by its frequency in sequences from unvaccinated individuals (Y-axis) versus its frequency in sequences from vaccinated individuals (X-axis). Data is divided by WHO variant classifications Alpha (A), Delta (B), and Omicron (C). Mutations observed along the diagonal depict mutations observed equally among vaccinated and unvaccinated individuals. Mutations observed moving away from the diagonal represent mutations observed in either vaccinated (X-axis) or unvaccinated (Y-axis) individuals. (D) Frequency of SNPs in SARS-CoV-2 sequences from unvaccinated (top) and vaccinated (bottom) individuals, by genome position (x-axis). In all panels, Alpha is represented by yellow circles, Delta by blue squares, and Omicron by red triangles.

References

    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. Dec 31 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577 - DOI - PMC - PubMed
    1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine. 2020;384(5):403–416. doi:10.1056/NEJMoa2035389 - DOI - PMC - PubMed
    1. Sadoff J, Gray G, Vandebosch A, et al. Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. New England Journal of Medicine. 2021;384(23):2187–2201. doi:10.1056/NEJMoa2101544 - DOI - PMC - PubMed
    1. Food and Drug Administration. Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2023. Updated June 16, 2023. Accessed August 10, 2023, https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-u...
    1. Centers for Disease Control and Prevention. COVID-19 Vaccinations in the United States. Updated May 11,2023. Accessed August 10, 2023, https://covid.cdc.gov/covid-data-tracker/#vaccinations_vacc-people-boost...

Publication types